Concepedia

Shyam Kalavar

SK

Statistics

Publications

10

Citations

601

H-Index

10

Active since

1995

Affiliations

Center for Devices and Radiological Health(Current)

United States Food and Drug Administration

Center for Drug Evaluation and Research

Merck & Co., Inc., Rahway, NJ, USA (United States)

Shyam Kalavar is an author at Center for Devices and Radiological Health specializing in oncology, medicine, and pharmacology.

Publications per year

1995–2024

10

Publications

10

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Preeti Narayan, Sakar Wahby, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 182 citations

, , +17

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Asma Dilawari, Mirat Shah, Gwynn Ison et al. · Clinical Cancer Research · 2023 · 105 citations · Full text

, , +11

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

Preeti Narayan, Asma Dilawari, Christy Osgood et al. · Journal of Clinical Oncology · 2023 · 52 citations

, , +17

FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Jianjin Xu, Chana Weinstock et al. · Journal of Clinical Oncology · 2023 · 50 citations

, , +16

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Luckson Mathieu, Erin Larkins, A. K. Sinha et al. · Clinical Cancer Research · 2023 · 46 citations · Full text

, , +17

1–5 of 10